Free Trial

Veracyte Q3 2023 Earnings Report

Veracyte logo
$40.89 +1.82 (+4.66%)
(As of 12/20/2024 05:51 PM ET)

Veracyte EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Veracyte Revenue Results

Actual Revenue
$90.11 million
Expected Revenue
$84.78 million
Beat/Miss
Beat by +$5.33 million
YoY Revenue Growth
N/A

Veracyte Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Veracyte Earnings Headlines

Veracyte (VCYT) Shares Rebounded in Q3
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Veracyte: Getting Frothy
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

View Veracyte Profile

More Earnings Resources from MarketBeat

Upcoming Earnings